ALSO NOTED: GSK boots flu vaccine supply; Novartis looks at mergers, buyouts;

> GlaxoSmithKline has boosted its supply of flu vaccine for the U.S. market by up to 10 million doses this season, to 30 to 35 million from 25 million last flu season. Release

> Officials in Kent, England, are asking Pfizer to help laid-off employees find new jobs when the company's manufacturing division there shuts down. Report

> Schering-Plough announced it's converting its preferred stock issued in 2004 to common stock at an exchange rate of 1 to 2.2466. Report 

> Novartis says it's looking selectively at mergers and buyouts as a growth option. Report

And Finally... Now it's time for a feel-good pharma-related piece: Child mortality is at a record low and is expected to keep dropping, thanks in part to vaccines. So let's keep that disease-prevention R&D coming. Article 

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.